Children's Hospital Medical Center, Cincinnati
Children's Hospital Medical Center, Cincinnati sponsors 571 registered US clinical trials on ClinicalTrials.gov, 106 of them currently recruiting, and 372 completed. 38 of these trials are in Phase 3-4 (later-stage) and 140 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Autism Spectrum Disorder, with 13 trials.
Trial Pipeline
571 total, page 6 of 12
CEGIR 7807: Validation of Online Cohort of EGID Patients Enrolled in RDCRN CEGIR Contact Registry
NCT03382678
FOREVR Peds VR Pilot
NCT04556747
Remote Ischemic Conditioning in HSCT
NCT04808167
Pharmacokinetic Study of Dexmedetomidine After Intra-Nasal and Buccal Dosing in Children
NCT03668951
ADHD/Me Bibliotherapy Study
NCT03620344
Kidney Fibrosis and MRI
NCT03964948
OT Intervention Via Telehealth for Children With ASD and ADHD
NCT03957993
Eculizumab to Treat Thrombotic Microangiopathy/Atypical Hemolytic Uremic Syndrome -Associated Multiple Organ Dysfunction Syndrome in Hematopoietic Stem Cell Transplant Recipients
NCT03518203
Does Montelukast Decrease Post Adenotonsillectomy Pain in Children
NCT02793375
Airway Clearance Therapy on Hyperpolarized 129Xenon and MRI
NCT03593434
Healthy Weight for Teens
NCT03939494
Shared-Decision Making for Hydroxyurea
NCT03442114
Evaluation of Helmet Technology and Head Impact Exposure
NCT03883451
Controlled DTI Evaluations in High School Football and Female Soccer to Evaluate Efficacy of Jugular Compression Collar
NCT04068883
Daily Living Skills Intervention for Adolescents With Autism Spectrum Disorder
NCT03984487
Development of Novel MRI Methods for Detecting, Discriminating, and Measuring Liver Fibrosis and Congestion in Fontan Patients
NCT03539757
Assessment of Urinary NGAL to Predict AKI in Children Receiving Multiple Nephrotoxic Medications
NCT03527160
Benralizumab for Eosinophilic Gastritis (BEGS)
NCT03473977
The Longitudinal Evaluation of Autoimmune Pulmonary Alveolar Proteinosis
NCT03531996
Personalized Research on Diet in Ulcerative Colitis and Crohn's Disease
NCT03301311
Identifying PARDS Endotypes
NCT03539783
Rx for Success: RCT of an App for Dialogic Reading Training
NCT03828721
Personalized Treatment Algorithms for Difficult-to-treat Asthma
NCT04179461
Hearing Aid Noise Reduction in Pediatric Users Pilot Study (Oticon Pilot Study)
NCT04469946
Brain Mechanisms of Juvenile Fibromyalgia
NCT03612258
A Randomized Trial of Vitamin D Supplementation With or Without Vitamin A in Stem Cell Transplantation
NCT03202849
Normal Liver Stiffness by MR Elastography
NCT03235414
Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults
NCT03445858
Clinical Use of a Neonatal MRI System
NCT03476343
Growth Hormone Treatment in Patients With Aggrecan (ACAN) Deficiency
NCT03288103
An Initial Study of AZD7325 in Adults With Fragile X Syndrome
NCT03140813
Fibromyalgia Integrative Training for Adolescents With Juvenile Fibromyalgia
NCT03268421
Fuzzy AI Using VR for Collision Prevention
NCT03915119
MigraineManager: An Individualized Self-Management Tool for Adolescents With Migraine
NCT03157739
A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG)
NCT03355794
Technology- Assisted Stepped Care Intervention Study
NCT03733457
Precision Dosing of Alemtuzumab
NCT03302754
CEGIR 7808: Use of Unsedated Transnasal Esophagoscopy (TNE) to Monitor Dietary Management of Eosinophilic Esophagitis in Children
NCT03342391
Gaining Real-Life Skills Over the Web
NCT05160194
Genomic Basis of Neurodevelopmental and Brain Outcomes in Congenital Heart Disease (CHD Brain and Genes)
NCT03070197
Effect of Elemental Diet on Adult Patients With Eosinophilic Gastroenteritis
NCT03320369
Teaching Academic Success Skills to Students With Autism Spectrum Disorders in Clinical Setting
NCT03606343
Pharmacokinetic and Pharmacodynamic Analysis of Ceftaroline in Children and Adolescents With Cystic Fibrosis
NCT03771313
IBD Shared Decision Making Intervention
NCT03228615
Open-label Study of Tofacitinib for Moderate to Severe Skin Involvement in Young Adults With Lupus
NCT03288324
Pioglitazone Therapy of Autoimmune Pulmonary Alveolar Proteinosis Autoimmune Pulmonary Alveolar Proteinosis
NCT03231033
Adaptive Care in the Perioperative Setting
NCT03353129
Comparison of MR Elastography Methods Without and With Compressed Sensing
NCT03260660
Head Start Family Navigator Intervention
NCT03499405
Evaluation of a Single Dose of Inhaled Sargramostim in Patients With Autoimmune Pulmonary Alveolar Proteinosis
NCT03006146
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 86 |
| Phase 2 | 54 |
| Phase 3 | 15 |
| Phase 4 | 23 |
Therapeutic Areas
What the Pipeline for Children's Hospital Medical Center, Cincinnati Shows
According to the ClinicalTrials.gov registry, Children's Hospital Medical Center, Cincinnati is linked to 571 US clinical trials across every stage of research activity. Of those, 106 studies are currently recruiting, about 19% of the sponsor's indexed portfolio, and 372 are already marked complete, representing roughly 65% of the total.
The phase mix for Children's Hospital Medical Center, Cincinnati reports 38 late-stage studies (Phase 3 and Phase 4 combined) and 140 earlier-phase studies (Phase 1 and Phase 2).
The top therapeutic focus area indexed for Children's Hospital Medical Center, Cincinnati is Autism Spectrum Disorder with 13 linked trials, and 9 other condition areas appear in the top list above.
How to read these pipeline numbers
Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work, safety, dosing, and early signal detection, and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice, verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.